EP0818995A1 - Systeme transdermique pourvu d'electrodes servant de systeme d'initialisation - Google Patents

Systeme transdermique pourvu d'electrodes servant de systeme d'initialisation

Info

Publication number
EP0818995A1
EP0818995A1 EP96909129A EP96909129A EP0818995A1 EP 0818995 A1 EP0818995 A1 EP 0818995A1 EP 96909129 A EP96909129 A EP 96909129A EP 96909129 A EP96909129 A EP 96909129A EP 0818995 A1 EP0818995 A1 EP 0818995A1
Authority
EP
European Patent Office
Prior art keywords
substance
transdermal system
layer
modification layer
transdermal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP96909129A
Other languages
German (de)
English (en)
Inventor
Carlo Stefan Effenhauser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH
Novartis AG
Original Assignee
Novartis Erfindungen Verwaltungs GmbH
Ciba Geigy AG
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Erfindungen Verwaltungs GmbH, Ciba Geigy AG, Novartis AG filed Critical Novartis Erfindungen Verwaltungs GmbH
Priority to EP96909129A priority Critical patent/EP0818995A1/fr
Publication of EP0818995A1 publication Critical patent/EP0818995A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0444—Membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0448—Drug reservoir

Definitions

  • the invention relates to a transdermal system for the passive administration of a substance according to the preamble of the independent claim.
  • transdermal systems serve to administer a substance, for example therapeutically active substances or mixtures of substances, through the skin of a living being, without using a device such as, for. B. an injection needle to mechanically clearly penetrate the outer layer of skin - the stratum corneum - and possibly also underlying skin layers.
  • Transdermal systems are therefore normally non-invasive forms of administration.
  • transdermal systems The great interest in transdermal systems is due to the fact that this form of administration has clear advantages over other customary methods.
  • undesirable side effects often occur due to incompatibilities in the gastrointestinal tract or in the liver.
  • Orally administered substances are often already decomposed in the gastrointestinal tract or in the liver or modified in such a way that the desired therapeutic effect no longer occurs ("first-pass" effect).
  • Other forms of parenteral administration such as intravenous, subcutaneous or intramuscular injections, are associated with skin penetration or skin layers and are therefore associated with a sensation of pain for the patient. Local inflammation or infection due to partial skin damage can also occur.
  • transdermal systems are not subject to these restrictions, today, in particular in the form of a typical representative, namely the transdermal patch, they are among the common dosage forms which are widely used.
  • Transdermal systems can be roughly divided into passive and active systems.
  • the substance to be administered diffuses through the skin from a reservoir.
  • an additional force accelerates substance transport through the skin.
  • Electrical fields that generate a current flow through the skin are particularly preferably used here.
  • the administration of a therapeutically active substance through the skin by means of an electric current is generally referred to as iontophoresis.
  • iontophoretic administration can also be used for uncharged active ingredients. For example, a convection flow that results from electroosmotic or osmotic forces transports the uncharged active ingredient through the skin
  • iontophoretic active systems used today include at least two electrodes, one of which contacts the reservoir with the substance.
  • the other electrode often referred to as an indifferent electrode, is attached directly to the skin and is used to close the circuit through the body.
  • an electrical energy source When connected to an electrical energy source, a current flows through the skin that transports the substance into the body.
  • iontophoretic administration has several disadvantages.
  • undesired hydrolysis or electrolysis effects can lead to degradation of the therapeutically active substance and / or to the formation of new, possibly toxic compounds.
  • the skin also represents an electrical resistance, which can vary widely depending on the patient and the current nature, in addition to the electrical energy source, control means must be provided in iontophoretic systems, which monitor and, if necessary, regulate the electrical current through the skin. Therefore, such systems are cost-intensive, technically and structurally very complex to manufacture.
  • the correct application of the system can often only be carried out by a specialist.
  • the current flow during the iontophoretic administration of a substance can lead to burns or other irritations of the skin.
  • the dosing rate can be influenced via the different concentrations, the different concentration gradients, the number and thickness of the individual layers and the type and amount of any carrier substance added.
  • a disadvantage of this method is that the dosing rate during the manufacture of the transdermal system is practically already determined and subsequent adjustment to the individual needs of the patient is no longer possible. This means that a different system has to be produced for each desired dosing rate, which is not efficient in terms of efficient mass production.
  • the manufacture of such a multilayer system with precisely coordinated layer thicknesses and substance concentrations is associated with considerable technical difficulties.
  • the transdermal system is also intended to avoid skin irritation and to be mass-produced easily and inexpensively. Furthermore, the transdermal system should be storable over a long period of time without any significant changes in its therapeutic effectiveness.
  • the transdermal system for the passive administration of a substance through the skin that achieves this object is characterized by the features of independent claim 1 characterized.
  • an electrical current thus transports the substance prior to the passive administration - e.g. B. before applying the system to the skin - from the reservoir into the transfer device.
  • the system is initialized in this way. This initialization of the system makes it possible to influence the amount of substance and the concentration of the substance in the transfer device in a controlled manner.
  • the concentration of the substance which is decisive for the diffusion-related dosing rate is no longer the concentration with which the substance is introduced into the reservoir during the manufacture of the system, but rather that which is generated by the initialization in the transfer device.
  • the transdermal system according to the invention thus has the property that the dosing rate for passive administration can still be influenced in a controllable manner after the system has been manufactured.
  • This has the advantage that different dosing rates can be achieved with transdermal systems that are produced in the same way, because the amount of substance or the concentration of the substance in the transfer device can be controlled via the strength of the current and the duration of the current flow during the initialization.
  • Such transdermal systems are therefore very well suited for efficient mass production.
  • the substance can also be concentrated during the initialization, which means that after the initialization in the transfer device, the substance is present in a higher concentration than before the initialization in the reservoir. This concentration leads to a significant increase in the dosing rate in the subsequent passive administration of the substance.
  • the transfer device comprises a modification layer whose electrical conductivity is greater than that of the reservoir. As will be explained further below, this can lead to the mentioned effect that the substance is concentrated during the migration from the storage layer into the modification layer that takes place during the initialization.
  • transdermal system can also be used for the administration of several substances. These can either be contained in the same storage layer or the reservoir can comprise a plurality of storage layers which are spatially separated from one another.
  • FIG. 1 shows a section through an embodiment of the transdermal system according to the invention with the essential parts
  • FIG. 2 shows a representation of a possible course of the electric field strength in the transdermal system according to the invention as a function of a spatial coordinate during the initialization
  • Fig. 3 shows a section through a development of the first embodiment of the transdermal system according to the invention with the essential parts and
  • Fig. 4 shows a section through a further embodiment of the transdermal system according to the invention with the essential parts.
  • the transdermal system 1 schematically shows an exemplary embodiment of the transdermal system according to the invention for the passive administration of a substance through the skin.
  • the transdermal system 1 comprises a reservoir, which in this exemplary embodiment consists of a storage layer 2 in which the one to be administered therapeutically active substance is included.
  • the transdermal system contains a modification layer 3 which functions as a transfer device and which is connected to the storage layer 2 as well as to the skin (not shown in FIG. 1) during the passive administration of the substance.
  • a first electrode 4 and a second electrode 5 are provided in the transdermal system, which are arranged before the substance is administered in such a way that the storage layer 2 and the modification layer 3 are located between the two electrodes 4 and 5.
  • the storage layer 2 and the modification layer 3 are made of an electrically conductive material, so that an electrical current can flow through these layers.
  • the storage layer 2 is preferably made from an ionically conductive polymer or gel, particularly preferably from a hydrogel, in which the substance to be administered is typically contained in dissolved form.
  • the modification layer is also preferably made from an ionically conductive polymer or gel, particularly preferably from a hydrogel. Both layers 2 and 3 can be made of the same material. Such polymer or gel materials are per se state of the art and are frequently used in known active and passive transdermal systems.
  • the system is initially initialized before the substance is passively administered through the skin. This means that before the actual administration and preferably before the system is in contact with the skin, an electrical current brings the transdermal system into the initial state desired for the administration.
  • the use of the transdermal system according to the invention is therefore divided into two phases, separated in time: first, substance is transported from the storage layer 2 into the modification layer 3 (initialization) by means of electric current, and then the passive - i.e. diffusion-induced - administration of the substance by Skin.
  • the modification layer 3 has a greater electrical conductivity than the storage layer 2. If both layers 2 and 3 are made of the same material, this difference in conductivity can be explained, for example, by different degrees of crosslinking of a gel realize.
  • a coordinate axis x is additionally introduced in FIG. 1, the origin 0 of which lies where the first electrode 4 and the storage layer 2 touch.
  • the storage layer 2 extends up to the x coordinate d-
  • the modification layer 3 extends from the x coordinate d 1 to the x coordinate d * + d 2 .
  • the two electrodes 4 and 5 connected to an electrical energy source, for example a battery (not shown in FIG. 1), such that the two electrodes 4 and 5 form a closed circuit with the energy source, the storage layer 2 and the modification layer 3
  • an electrical current can flow, which transports the substance from the storage layer 2 into the modification layer 3.
  • the modification layer 3 and the storage layer 2 form a series connection of two resistors, and since the electrical conductivity of the modification layer 3 is greater than the electrical conductivity of the storage layer 2, the voltage drop across the storage layer 2 is greater than the voltage drop across the modification layer 3.
  • the corresponding course of the electric field strength E as a function of the coordinate x, as defined in FIG. 1, is shown in FIG. 2.
  • the electrophoretic mobility of the substance in the storage layer 2 is essentially the same as in the modification layer 3. This requirement is only for better understanding, but is not necessary for the invention.
  • the transdermal system according to the invention can also be designed in such a way that the mobilities of the substance in the storage layer 2 and in the modification layer 3 differ.
  • the rate of migration of the substance is essentially determined by the product of the local electric field strength and the electrophoretic mobility, it follows, provided the same mobility of the substance in the storage layer 2 and the modification layer 3, that the rate of migration of the substance mainly depends on the respective electric field strength in layers 2 and 3
  • the rate of migration of the substance mainly depends on the respective electric field strength in layers 2 and 3
  • the substance at the transition from the storage layer 2 with lower conductivity and greater electric field strength into the modification layer 3 with greater conductivity and smaller electrical field strength is "braked".
  • the substance therefore has different migration rates in the two layers 2 and 3. This difference in the migration rates has the consequence that the concentration of the substance in the modification layer 3, in which the migration rate is lower, increases.
  • the substance is concentrated in the modification layer 3.
  • Such a transdeirnal system has therefore the advantage that the substance to be administered is available in the modification layer 3 after the initialization in a concentration which is significantly higher than the original concentration with which the substance was contained in the storage layer 3 before the initialization.
  • This increase in concentration results in a considerably higher dosing rate in the subsequent passive administration.
  • This concentration of the substance during the initialization also has a particularly advantageous effect in those cases in which the substance cannot be stored for a prolonged period in such a high concentration that is necessary for efficient passive administration
  • the transdermal system 1 according to the invention it is by no means necessary for the transdermal system 1 according to the invention and in particular for the concentration of the substance in the modification layer 3 that the electrophoretic mobility of the substance is the same in the two layers.
  • concentration for example, it is only essential that the migration speed of the substance in the modification layer 3 is significantly lower than in the storage layer 2. This can also be achieved, for example, by having the same in the storage layer 2 and in the modification layer 3 with the same electric field strength electrophoretic mobility of the substance in the two layers 2 and 3 is different.
  • the concentration with which the substance is contained in the modification layer 3 at the end of the initialization there are two parameters available for this control: on the one hand the strength of the electrical current that flows during the initialization, and on the other hand the duration of the initialization.
  • the current intensity influences the amount of substance that migrates from the storage layer 2 into the modification layer 3, the duration of the initialization determines how long the substance migrates due to electrical forces.
  • a suitable combination of current strength and duration can thus introduce a certain amount of substance into the modification layer 3. Since the modification layer 3 preferably has the property that the concentration equalization by means of diffusion takes place rapidly in comparison to the electrically caused migration, a specifically desired concentration of the substance in the modification layer 3 can be achieved. Since the electrical current only flows through the skin during initialization and therefore not through it, the current intensity is not subject to any physiological limitation.
  • the passive system according to the invention consequently has the great advantage that the concentration of the substance to be administered can be modified in a controlled manner even after production, in which the substance is introduced into the storage layer with a certain concentration, which makes the system suitable for efficient mass production is suitable.
  • the transdermal system 1 can of course also be designed such that the concentration of the substance to be administered in the modification layer at the end of the initialization is lower than the original concentration with which the substance was contained in the storage layer 3 before the initialization.
  • This can be achieved, for example, by the fact that the storage layer has a higher electrical conductivity than the modification layer 3.
  • the electric field strength in the modification layer 3 is greater than in the storage layer 2.
  • the substance has essentially the same mobility in the two layers 2 and 3 a higher migration rate in the modification layer 3 and thus a lowering of the concentration.
  • the higher migration rate in the modification layer can of course also be caused - alternatively or in addition to the different electric field strength - by different electrophoretic mobilities of the substance in the storage layer 2 and in the modification layer 3.
  • the substance to be administered is in a desired concentration controllable by the initialization in the modification layer 3.
  • the initialization is ended by interrupting the storage layer consisting of the two electrodes 4 and 5, the energy source 2 and the modification layer 3 circuit formed. This can happen, for example, in such a way that the second electrode 5, or also remove both electrodes 4 and 5 by pulling them off the transdermal system 1.
  • the transdermal system is now ready for passive administration of the substance.
  • the transdermal system is fixed on the patient's skin after removal of the second electrode 5 such that the modification layer 3 contacts the skin.
  • the transdermal system according to the invention is particularly preferably designed in the form of a plaster and covered with an adhesive layer.
  • the attachment to the skin is then carried out in a manner known per se as in the case of a conventional passive transdermal patch. Since the second electrode 5, or both electrodes 4 and 5, is separated from the transdermal system before the substance is administered, it can be designed in such a way that it also serves as a protective agent during storage of the system. After the transdermal system according to the invention is attached to the skin, the substance to be administered can passively pass through the skin, that is to say by means of diffusion.
  • intermediate layers 4a and 5a are provided between the first electrode 4 and the storage layer 2 and between the modification layer 3 and the second electrode 5. They spatially separate the first electrode 4 from the storage layer 2 and the second electrode 5 from the modification layer 3.
  • the intermediate layers 4a and 5a prevent contamination of the storage layer 2 and the modification layer 3, respectively, because the intermediate layers 4a and 5a keep electrolysis products from the storage layer 2 and in particular the modification layer 3 during the current flow from the electrodes 4 and 5.
  • the electrolyte contained in the intermediate layers 4a and 5a helps to close the circuit.
  • the intermediate layer 5a together with the second electrode 5 can be removed from the transdermal system 1 by pulling it off.
  • both intermediate layers 4a and 5a can be removed together with the respective electrodes 4 and 5 after the initialization.
  • the transdermal system in the development shown in FIG. 3 has a barrier membrane 10 which is arranged between the storage layer 2 and the modification layer 3.
  • This barrier membrane 10 has the property that its permeability can be controlled by applying an electric field. Before the initialization of the transdermal system, the electrical field between the electrodes has not yet been switched on and thus the barrier membrane 10 has practically no permeability. If the electric field is switched on to initialize the transdermal system, the barrier membrane 10 "opens" and the substance to be administered can wander through them. Membranes such as the barrier membrane 10 are per se state of the art.
  • barrier membrane 10 has the advantage that the transdermal system can be stored better and longer, because during storage the barrier membrane 10 leads to a more permanent separation of the storage layer 2 and the modification layer 3, which indeed have phases with different physical and chemical properties (e.g. conductivity).
  • the barrier membrane 10 prevents prior to initialization, i. H. as long as the circuit is not yet closed, that a substantial mass transport, for example by passive diffusion, takes place between the storage layer 2 and the modification layer 3.
  • the barrier membrane 10 practically does not hinder the migration of the substance during the initialization of the transdermal system, that is to say in the open state.
  • therapeutically active substances can also be administered with the system according to the invention. These substances can, for example, be contained in the same storage layer 2 and then migrate together into the modification layer 3 during the initialization.
  • the reservoir comprises more than one storage layer 2.
  • the reservoir comprises two storage layers 2a and 2b. These storage layers 2a and 2b are preferably arranged in a stack and spatially separated from one another, so that the reservoir has a multilayer structure.
  • This exemplary embodiment is particularly advantageous for the administration of a plurality of different substances if the different substances cannot be stored in a storage layer for a long time together with a concentration which is sufficiently high for passive administration. The substances then migrate from the different storage layers 2a and 2b into the modification layer 3 during the initialization and are brought there to the desired concentration.
  • the number of two storage layers 2a and 2b is to be understood purely as an example.
  • the reservoir can also contain more than two storage layers.
  • different storage layers 2a and 2b can also contain the same substance with different concentrations. This means that, during the initialization, the whole of the Modification layer 3 and the storage layers 2a and 2b generate a concentration profile with which, for example in the subsequent passive administration, a dosing rate that is constant over time can be achieved.
  • the storage layers 2a and 2b and the modification layer 3 are also preferably made of an ionically conductive polymer or gel, particularly preferably of a hydrogel, in the melir layer structure.
  • the material from which the modification layer 3 is made can be the same material that is used to produce the storage layers 2a and 2b.
  • all of the storage layers 2a and 2b and the modification layer 3 can be produced from the same polymer or gel material.
  • the different migration speeds of the substance in the different layers 2a, 2b and 3 can then be realized by different degrees of crosslinking in the individual layers 2a, 2b and 3, because the conductivity and thus the electric field strength in a certain layer during the initialization depends on the degree of crosslinking this layer.
  • intermediate layers can also be provided on one or both electrodes 4 and 5, which keep electrolysis products away from the storage layers 2a and 2b or from the modification layer 3.
  • barrier membranes can be provided between the modification layer 3 and the adjacent storage layer 2b, and / or between adjacent storage layers 2a and 2b, the permeability of which can be controlled by the electric field.
  • the transdermal system according to the invention in which an electrically driven transport of the substance into the modification layer 3 takes place prior to the passive administration of the substance, has the great advantage that the concentration of the substance to be administered also after production, in which the substance with a certain concentration is introduced into the storage layer 2, can be modified in a controlled manner.
  • the dosing rate can be adapted to the individual therapeutic needs of a patient, which makes the transdermal system very flexible with regard to its use.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Electrotherapy Devices (AREA)
  • Medicinal Preparation (AREA)
  • Media Introduction/Drainage Providing Device (AREA)

Abstract

L'invention concerne un système transdermique (1) d'administration passive d'une substance à travers la peau, qui comprend un réservoir comportant une couche de stockage (2) pour les substances à administrer, ainsi qu'un dispositif de transfert. Pendant le processus d'administration, ce dispositif de transfert est aussi bien en contact avec le réservoir qu'avec la peau. Il est également prévu dans ce système transdermique (1) des électrodes (4, 5) qui produisent un courant qui initialise le système et sert à transporter la substance de la couche de stockage dans une couche de modification (3) contenue dans le dispositif de transfert. Ce système transdermique (1) permet également d'administrer plusieurs substances à travers la peau d'un patient.
EP96909129A 1995-04-07 1996-03-26 Systeme transdermique pourvu d'electrodes servant de systeme d'initialisation Ceased EP0818995A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP96909129A EP0818995A1 (fr) 1995-04-07 1996-03-26 Systeme transdermique pourvu d'electrodes servant de systeme d'initialisation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP95810233 1995-04-07
EP95810233 1995-04-07
EP96909129A EP0818995A1 (fr) 1995-04-07 1996-03-26 Systeme transdermique pourvu d'electrodes servant de systeme d'initialisation
PCT/EP1996/001328 WO1996031200A1 (fr) 1995-04-07 1996-03-26 Systeme transdermique pourvu d'electrodes servant de systeme d'initialisation

Publications (1)

Publication Number Publication Date
EP0818995A1 true EP0818995A1 (fr) 1998-01-21

Family

ID=8221726

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96909129A Ceased EP0818995A1 (fr) 1995-04-07 1996-03-26 Systeme transdermique pourvu d'electrodes servant de systeme d'initialisation

Country Status (5)

Country Link
EP (1) EP0818995A1 (fr)
JP (1) JPH11503044A (fr)
AU (1) AU5274196A (fr)
CA (1) CA2217061A1 (fr)
WO (1) WO1996031200A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5797867A (en) * 1996-09-27 1998-08-25 Becton Dickinson And Company Iontophoretic drug delivery system, including method for activating same for attachment to patient

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE399044A (fr) * 1933-09-09
AU609769B2 (en) * 1987-02-10 1991-05-09 Drug Delivery Systems Inc. Electrolytic transdermal delivery of proteins
DE4014913C2 (de) * 1990-05-10 1996-05-15 Lohmann Therapie Syst Lts Miniaturisiertes transdermales therapeutisches System für die Iontophorese
US5356632A (en) * 1991-09-12 1994-10-18 S.I. Scientific Innovations Ltd. Transdermal drug delivery device
US5298017A (en) * 1992-12-29 1994-03-29 Alza Corporation Layered electrotransport drug delivery system
DE9316261U1 (de) * 1993-10-25 1994-02-03 Tyco Healthcare Deutschland Manufacturing GmbH, 93333 Neustadt Hydrogelkörper auf der Basis von Acrylsäure

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9631200A1 *

Also Published As

Publication number Publication date
JPH11503044A (ja) 1999-03-23
WO1996031200A1 (fr) 1996-10-10
AU5274196A (en) 1996-10-23
CA2217061A1 (fr) 1996-10-10

Similar Documents

Publication Publication Date Title
EP0819016A1 (fr) Systeme transdermique iontophoretique permettant d'administrer au moins deux substances
EP0892653B1 (fr) Systeme d'electrodes
EP0796128B1 (fr) Systeme transdermique
DE60036306T2 (de) System zur verabreichung von medikamenten mit veränderbarer rate
DE69930306T2 (de) Kombinierte elektroporation- und iontophoresevorrichtung zur medikament- und genverabreichung
DE69427526T2 (de) Applikator zur transkutanen verabreichung eines medikaments
DE60110980T2 (de) Katheterleitung zur Implantation in den Intrathekalraum
DE69429634T2 (de) Elektrokatheter zur sequentiellen Herzreizung (DDD) mit einer durch den Sinus coronarius eingeführten einzigen Leitung
DE19518932C2 (de) Vorrichtung zur Perforation der Haut für die Vorbereitung einer transdermalen Medikation
DE69204676T2 (de) Transdermale abgabevorrichtung.
DE3688463T2 (de) Einrichtung zur transdermalen Applikation von Heilmitteln und dazugehörige Elektroden.
DE3789642T2 (de) Apparat zur iontophoretischen behandlung mit medikamenten.
DE69212468T2 (de) Gerät zur verminderung der empfindung während der iontophoretischen arneimittelverabreichung
DE60020159T2 (de) Hautbehandlungsvorrichtung zur verlängerten transdermalen verabreichung von medikamenten
DE69214158T2 (de) Iontophoretische verbreichungsvorrichtung und versorgungsnetz dafür
DE69431189T2 (de) Iontophoresegerät
DE69927388T2 (de) Gerät zur verabreichung von medikamenten und genen in gewebe
DE68911389T2 (de) Medizinische Vorrichtungen.
EP2429382B1 (fr) Aiguille d'insertion de capteur pouvant etre commandee
DE69029399T2 (de) Vorrichtung für Iontophorese unter Verwendung einer Durchfluss-kontrollierenden Membran
DE2825232A1 (de) Vorrichtung zur verabreichung von arzneimitteln
DE69310844T3 (de) Benutzeraktivierte, iontophoretische vorrichtung
DE69504207T2 (de) Ionophoretische vorrichtung zur transdermalen verabreichung von medikamenten undentsprechende wegwerfeinheit
DE69806794T2 (de) Kombinierte elektroporation-und iontophoresevorrichtung zur medikament-und genverabreichung
EP0818995A1 (fr) Systeme transdermique pourvu d'electrodes servant de systeme d'initialisation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970917

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.

Owner name: NOVARTIS AG

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

17Q First examination report despatched

Effective date: 20010330

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.

Owner name: NOVARTIS AG

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20011125